Q1 2025 Company Update

FINANCING

We are pleased to announce that Cubed Biotech Inc. (“Cubed”) closed a debenture financing on New Year’s Eve for aggregate gross proceeds of USD$500,000. This includes a lead anchor order by a third-party investor that has executed a non-binding term sheet for a common share financing in the aggregate amount of USD$15 million.

Cubed’s current proposed transaction relates to a convertible debenture financing (the “Convertible Debenture Financing”), and we are seeking an additional USD$100,000 to USD$500,000 to close the round.

Please let us know if you would like to review the Convertible Debenture Financing term sheet.

Investment Outreach Strategy

Cubed’s CEO Adam met with 160 investors in New York earlier this year, and we successfully raised funds through exercised options and new cash investments.

Non-hallucinogenic Molecule Drug Development

CB-002 “Ocelot”: A Breakthrough in Non-Hallucinogenic Psychedelic Drug Discovery

Cubed is proud to announce significant progress in its drug discovery plans. Our efforts are intended to create a drug that retains the anti-depressant and anti-anxiety benefits of psychedelics without inducing hallucinations, making it more accessible to a broader patient population.  If we can remove or mitigate these side effects, we expect the drug will be more accessible and may improve patient compliance, expanding its potential to treat a broader patient population.

Our medicinal chemist has initiated the discovery phase for a novel class of non-hallucinogenic hybrid psychedelic molecules.  We have identified 50 potential unpatented molecules that has the potential to revolutionize mental health treatments by offering the therapeutic benefits of psychedelics without the hallucinogenic side effects. This innovation not only positions Cubed at the cutting edge of psychedelic research but also opens doors to more traditional funding opportunities, particularly within Quebec’s biotechnology sector.

License Renewal

We have successfully received a two-year renewal of our Dealers License from Health Canada. We are now permitted to make up to 6 kilograms of psilocybin, among other psychedelic molecules including 3,4-Methylenedioxymethamphetamine (“MDMA”).